Drug Development
Biopharmaceutical company initiates clinical trial of TRX4 for psoriasis
Published in Medical Letter on the CDC and FDA, September 5th, 2004
This phase 1 trial will be a single-dose, dose-escalation study to establish the safety, pharmacokinetic, and pharmacodynamic profile of TRX4. Approximately thirty moderate to severe psoriasis subjects will be enrolled. The clinical trial is being conducted pursuant to an investigational new drug (IND) application filed with the U.S. Food and Drug Administration.
TRX4 is a humanized monoclonal antibody that binds to a receptor found on all mature T cells called CD3, which is involved in normal T cell...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Alcoholism
Mass media campaigns effective for reducing alcohol-involved crashes - Diabetes Survival & Mortality
Diabetes increases cancer mortality risk for some cancer types - Food-Borne Illness
Antimicrobial drug delivery in food animals reviewed - HIV/AIDS Epidemiology
American Indians and Alaska natives surveilled for HIV/AIDS and risk behaviors - Malaria
Retrospective of re-infection of humans with Plasmodium published - AIDS/HIV Pathogenesis
Malnutrition increases risk of acquired immunodeficiency syndrome - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
